Regeneration Technologies, Inc. (RTI) and Tutogen Medical, Inc. today announced that with the proposed merger of the two companies, they will ask RTI shareholders to approve a new company name - RTI Biologics, Inc. The stock will continue to trade on the Nasdaq Global Market under RTI's trading symbol, RTIX.

On 13 November 2007 the two had companies announced  signing a definitive agreement to combine the two companies in a tax-free stock-for-stock exchange. Under the terms of the merger agreement, Tutogen shareholders will receive 1.22 shares of newly issued RTI common stock in exchange for each share of Tutogen common stock they own.

Upon completion of the merger, RTI and Tutogen stockholders would own approximately 55 per cent and 45 per cent respectively of the combined company on a diluted basis.

The newly combined and newly named company RTI Biologics will be positioned as a leader in biologics, a growing area in the healthcare industry and a key strength for both companies.

"Our new company name is centred around 'Biologics,' which can include a wide array of biological solutions. These are areas that represent strong growth and great promise in healthcare," said Brian K. Hutchison, RTI's chairman, president and CEO. "We feel it is important to begin this new endeavour with a fresh brand that better represents the strengths of both RTI and Tutogen"

While the company name will become RTI Biologics, the combined company will continue to use and leverage the strengths of both the BioCleanse and Tutoplast brand names, which are well-known throughout the medical community as the standards for sterilisation, safety and quality of orthopaedic and membrane tissues, respectively.

Special meetings of the RTI and Tutogen stockholders to consider and vote upon the transactions contemplated by the proposed merger with Tutogen, has been scheduled for 27 February at their respective headquarters.

RTI processes allograft and xenograft tissue into shaped implants for use in orthopaedic and other surgeries with a commitment to science, safety and innovation. It also holds the patents on BioCleanse, a proven tissue sterilisation process validated to eliminate viruses, bacteria, fungi and spores from tissue without impacting the structural or biomechanical integrity of the tissue. The company has distributed more than half a million allograft implants sterilised with the BioCleanse process with zero incidence of infection. RTI is accredited by the American Association of Tissue Banks.

Tutogen Medical, Inc. manufactures sterile biological implant products made from human (allograft) and animal (xenograft) tissue. It utilises its proprietary Tutoplast Process of tissue preservation and viral inactivation to manufacture and deliver sterile bio-implants used in spinal / trauma, urology, dental, ophthalmology, and general surgery procedures. Tutogen's Tutoplast products are sold and distributed worldwide by Zimmer Spine and Zimmer Dental (subsidiaries of Zimmer Holdings, Inc.), Davol Inc. (a subsidiary of C R Bard Inc.), the Mentor Corporation (Mentor), Coloplast Corporation, IOP, Inc. and through independent distributors internationally.